Skip to Content Facebook Feature Image

Print Creates an Enterprise Dark Data Problem. VasionⓇ Innovated Again to Find the Solution.

Business

Print Creates an Enterprise Dark Data Problem. VasionⓇ Innovated Again to Find the Solution.
Business

Business

Print Creates an Enterprise Dark Data Problem. VasionⓇ Innovated Again to Find the Solution.

2026-06-22 20:04 Last Updated At:20:10

SAINT GEORGE, Utah--(BUSINESS WIRE)--Jun 22, 2026--

Every time employees click File > Print to send documents to printers, save them to PDFs or scan them to unmanaged folders, enterprise data becomes unstructured and quietly goes dark. Dark data escapes compliance controls, bypasses AI workflow and quickly becomes a liability.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260622562749/en/

Gartner ® reports that “roughly 80% of enterprise information is unstructured, spread across documents, files, and rich content in dozens of systems.” Gartner ® also predicts that “by 2028, large enterprises will triple their unstructured data capacity across their on-premises, edge and public cloud locations.” AI is accelerating the trend, not reversing it: As employees use AI tools to generate larger documents in higher volume and continue to send them through the broken File > Print workflow the problem is getting worse. Dark data has become one of the fastest-growing challenges in enterprise IT.

Today, Vasion announces the availability of Intelligent Print Automation (IPA) so organizations can leverage that File > Print muscle memory of the workforce to keep data from going dark by seamlessly integrating with any application to intelligently route documents to virtually any destination, ensuring your organization's business intelligence does not go dark. Nowhere are the stakes higher than in healthcare, where patient data locked in unmanaged documents can compromise care decisions, HIPAA compliance, and clinical outcomes.

“Rural health organizations face the same challenge as every enterprise, critical information locked in documents that never make it into the systems driving care decisions. Vasion's Intelligent Print Automation addresses exactly that gap. We're excited to see Vasion bringing this kind of innovation to an infrastructure problem that has been overlooked for too long,” said Kasey Shakespear, Executive Director, Rural Health Association of Utah.

The pattern extends well beyond healthcare. Industry analysts see the same trajectory across every sector where compliance pressure is rising and AI is reshaping how documents move.

“As the management of documents, both print and digital, increasingly requires adherence to complex and evolving compliance requirements, organizations looking to modernize their document management are expected to increasingly rely on secure, seamlessly integrated, AI-driven compliance solutions for print and digital workflows,” said Geoffrey Wilbur, Research Manager, Imaging Domain, IDC.

That convergence is exactly what Intelligent Print Automation was built to address, and the company's leadership is candid about why others in the space can't follow.

“The market that was supposed to solve this problem was full of companies rolling up acquisitions, squeezing margins, killing innovation, and calling old hosted software SaaS. We took a different path: a substantial, multi-year R&D investment to build a cloud-native, multi-tenant platform with fully immutable microservices that was ready for single-click AI integration. Intelligent Print Automation is here, and we built it,” said Ryan Wedig, Co-Founder and CEO, Vasion.

For existing Vasion customers, the path to IPA starts with infrastructure they already have. For new customers, it's a single platform entry point that replaces what would otherwise require multiple vendors and months of integration work. The result is the same: eForms, eSignature, intelligent document processing, and no-code workflow automation, cloud-native and built to the security standards demanded by the most regulated industries in the world, including FedRAMP ® High Authorization.

About Vasion

Vasion ® is an Intelligent Print Automation company on a mission to make digital transformation attainable for everyone. For more than a decade, Vasion pioneered the cloud-native, serverless print management category, with 14,000+ customers and 30M+ agents deployed on enterprise endpoints worldwide. The Vasion platform, powered by PrinterLogic, PrinterLogic Output, and Vasion Automate, gives organizations the ability to modernize print, consolidate output management, and automate document workflows through a single pane of glass across every print and scan environment. Vasion serves customers globally across government, healthcare, manufacturing, financial services, and education. Learn more at vasion.com. Smart Starts Here.

Forward-Looking Statements Disclosures

Statements in this release about future products, features, and authorizations are forward-looking and subject to change; actual results may differ, and Vasion undertakes no obligation to update them. Vasion and PrinterLogic are registered trademarks of Vasion, Inc. Intelligent Print Automation and IPA are trademarks of Vasion, Inc. All other trademarks are the property of their respective owners.

Sources

Gartner, Navigating the Solutions Landscape for Managing Documents, Marko Sillanpaa, 26 February 2026.

Gartner, Manage Unstructured Data Risk and Growth With Data Storage Management Services, Rizvan Hussain, Michael Hoeck, 22 May 2026.

GARTNER is a trademark of Gartner, Inc. and/or its affiliates. Statements in this release about future products, features, and authorizations are forward-looking and subject to change; actual results may differ, and Vasion undertakes no obligation to update them.

"In the age of AI, where unstructured data is creating dark data at an unprecedented rate, Intelligent Print Automation has to be your game plan. It's not a nice-to-have. It's a must-have. You need the ability to do it in a way that allows you to move it into an agentic workflow that leverages tokens and the cost of probabilistic models. But in many cases, it makes more sense to have a bulletproof, deterministic workflow, and you have to be able to choose which flow that document is going to move through. These are the tools you have to have in your hands. You have to have it now, because this is not a future thing. This is a now thing, and Intelligent Print Automation, luckily, is here. It's available. It's the Vasion Automate Platform, and it's now," said Vasion Co-Founder & CEO Ryan Wedig.

"In the age of AI, where unstructured data is creating dark data at an unprecedented rate, Intelligent Print Automation has to be your game plan. It's not a nice-to-have. It's a must-have. You need the ability to do it in a way that allows you to move it into an agentic workflow that leverages tokens and the cost of probabilistic models. But in many cases, it makes more sense to have a bulletproof, deterministic workflow, and you have to be able to choose which flow that document is going to move through. These are the tools you have to have in your hands. You have to have it now, because this is not a future thing. This is a now thing, and Intelligent Print Automation, luckily, is here. It's available. It's the Vasion Automate Platform, and it's now," said Vasion Co-Founder & CEO Ryan Wedig.

Vasion is the Intelligent Print Automation leader making digital transformation attainable for all by eliminating print servers, consolidating print environments, digitizing and automating workflows.

Vasion is the Intelligent Print Automation leader making digital transformation attainable for all by eliminating print servers, consolidating print environments, digitizing and automating workflows.

MINNEAPOLIS--(BUSINESS WIRE)--Jun 22, 2026--

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platforms, today announced the closing of a new financing round with participation from Reed Jobs and Yosemite, whose aim is to “make cancer non-lethal in our lifetime,” alongside several new strategic investors. Additional financing terms were not disclosed.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260622435314/en/

The financing comes amid significant momentum for HistoSonics as the company continues to expand clinical adoption of histotripsy for liver tumors around the world and is quickly advancing additional applications of its non-invasive platform across solid tumors.

"Building a generational company requires partners who bring more than capital,” commented Mike Blue, Chairman & CEO, HistoSonics. “This financing continues to add strategic investors who understand our mission, appreciate the magnitude of the opportunity ahead, and share our commitment to delivering lasting value for patients, physicians, and shareholders."

Over the past year, HistoSonics has accelerated commercial and clinical progress in the destruction of liver tumors, including metastatic disease, with growing physician adoption and increasing utilization at leading academic medical centers and health systems. The company recently submitted a De Novo request to the U.S. Food and Drug Administration (FDA) seeking clearance for the destruction of kidney tumors, representing a major expansion opportunity for histotripsy.

In addition, HistoSonics continues to generate encouraging clinical experience in the treatment of primary pancreatic tumors, an area with profound unmet patient need. The company is advancing toward an anticipated FDA submission for pancreatic applications as clinical and technical milestones continue to be achieved.

“Yosemite’s mission is to help accelerate technologies that have the potential to meaningfully change outcomes for patients,” said Reed Jobs. “And for me it’s a personal mission. HistoSonics is pioneering an entirely new approach to addressing some of the world’s deadliest cancers and diseases, and we are excited to support the company as it expands the reach of histotripsy throughout the entire body.”

Histotripsy is a non-invasive therapeutic platform that uses focused ultrasound energy and acoustic cavitation to mechanically destroy targeted tissue without surgery or radiation, and with potentially fewer side effects than traditional therapies. The Edison Histotripsy System received U.S. FDA De Novo clearance for the destruction of liver tumors and has since seen expanding clinical adoption across the United States and internationally. Use of the Edison Histotripsy System in applications outside of the liver is limited to investigational use.

The proceeds from the financing will support continued commercial expansion, clinical development programs, additional regulatory initiatives, and further advancement of HistoSonics’ pipeline applications.

About HistoSonics

HistoSonics is a privately held medical device company developing a non-invasive platform and proprietary sonic beam therapy utilizing the science of histotripsy, a novel mechanism of action that uses focused ultrasound to mechanically destroy and liquefy unwanted tissue and tumors. The company is currently focused on commercializing their Edison System in the US and select global markets for liver treatment while expanding histotripsy applications into other organs like kidney, pancreas, prostate, and others. HistoSonics has offices in Ann Arbor, MI, Madison, WI, and Minneapolis, MN. For more information on the Edison Histotripsy System please visit: www.histosonics.com. For patient-related information please visit: www.myhistotripsy.com.

HistoSonics Edison® Histotripsy System

HistoSonics Edison® Histotripsy System

Recommended Articles